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Abstract
Purpose:   A systematic review of the literature was carried out to determine the role of
prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC) .
Methods:  To be eligible, full published trials needed to deal with SCLC and to have randomly
assigned patients to receive PCI or not. Trials quality was assessed by two scores (Chalmers and
ELCWP).
Results:  Twelve randomised trials (1547 patients) were found to be eligible. Five evaluated the
role of PCI in SCLC patients who had complete response (CR) after chemotherapy. Brain CT scan
was done in the work-up in five studies and brain scintigraphy in six. Chalmers and ELCWP scores
are well correlated (p < 0.001), with respective median scores of 32.6 and 38.8 %. This meta-
analysis based on the available published data reveals a decrease of brain metastases incidence
(hazard ratio (HR): 0.48; 95 % confidence interval (CI): 0.39 - 0.60) for all the studies and an
improvement of survival (HR: 0.82; 95 % CI: 0.71 - 0.96) in patients in CR in favour of the PCI arm.
Unfortunately, long-term neurotoxicity was not adequately described .
Conclusions:  PCI decreases brain metastases incidence and improves survival in CR SCLC
patients but these effects were obtained in patients who had no systematic neuropsychological and
brain imagery assessments. The long-term toxicity has not been prospectively evaluated. If PCI can
be recommended in patients with SCLC and CR documented by a work-up including brain CT scan,
data are lacking to generalise its use to any CR situations.
Introduction
Small cell lung carcinoma (SCLC) has a very poor prog-
nosis when untreated. The development of chemothera-
py, with or without chest radiotherapy, has allowed to
obtain survival improvement and a small percentage of
cures. However the majority of the patients relapse and
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only <25 % of complete responders will be long-term
survivors [1].
The central nervous system (CNS) is a frequent site of re-
lapse. About 10 % of the patients initially present with
brain metastases. The two-year cumulative risk rises to ≥
50 % [2] and CNS metastases are found in up to 65 % of
patients at autopsy [3]. The median survival time after
brain metastases diagnosis is 4 to 5 months. Because the
blood-brain barrier has been considered to protect the
CNS from most cytotoxic agents and as SCLC is very ra-
diosensitive, the role of prophylactic brain irradiation
(PCI) has been studied in several trials. The results of the
randomised trials show that PCI reduces the frequency
of brain metastases although survival is not consistently
improved. Some data suggest that the gain in survival is
restricted to patients in complete remission (CR). A re-
cently published meta-analysis [4] of PCI for SCLC in pa-
tients with CR after chemotherapy has analysed the data
of 7 randomised studies (including one abstract and one
unpublished study) concerning a total of 987 patients
(526 treated with PCI and 461 controls). The relative risk
(RR) of death in the treatment group as compared to the
control group was 0.84 (95 % confidence interval CI:
0.73 to 0.97; p= 0.01). PCI decreased also the cumulative
incidence of brain metastases (RR: 0.46; CI 95 %: 0.38 -
0.57; p < 0.001). Unfortunately the authors have not
mentioned the performance of cerebral imagery (CT scan
or MRI) in the work-up or the follow-up and have not re-
viewed the cerebral toxicity of PCI. Some articles have
dealt with this question. Johnson [5] reported 20 long-
term SCLC survivors with a median follow-up of 6 years
(2.4 to 10.6 y). Fifteen SCLC were treated by PCI, 2 by
therapeutic cranial irradiation and 3 had no cranial irra-
diation. Fifteen had neurologic complaints (memory
loss, walking or writing difficulties, weakness...), 15 had
abnormal brain CT scan (ventricular dilatation, brain at-
rophy...) and 12 had abnormal mental status examina-
tion. Neurologic abnormalities seemed thus to be very
common in long-term survivors SCLC and may be more
prominent in patients having received high-doses chem-
otherapy or treated with large brain radiotherapy frac-
tions. Lee [6] reported 3 cases of dementia, confusion
and ataxia over 24 patients who received PCI. There was
no toxicity in the control group. Toxicity appeared 2.5
years after PCI, the follow-up ranging from 37 to 74
months. In the Chake's study [7], five out of seven pa-
tients had progressive dysfunction leading to death in 1
to 26 months after PCI. Foncesca [8] related 14 % leu-
coencephalopathy in patients with SCLC who received
PCI. The mean time of onset of symptoms was 357 days,
the median follow-up time being 59 months. Symptoms
consisted of intellectual change, memory loss and motor
abnormalities. Laukkanen [9] related 60 % memory loss
but no dementia two years after PCI. In the Licciardelo
study [10], severe neurologic toxicities occurred in two of
15 patients (2.5 and 30 months after PCI). Finally, Van
Oosterhout [11] reported no statistical evidence for addi-
tional neurotoxicity (follow-up of 2 years) in a series of 51
patients whatever they had received or not PCI. But there
was difference in the neuro-psychological examination
between patients and matched healthy controls, that
might indicate that cognitive impairment is partly dis-
ease-related (probably due to emotional distress and de-
teriorated physical conditions). All these studies being
taken in consideration, the problem of cerebral toxicity
remains unclear, leading to controversy about the indi-
cations of PCI in SCLC.
The purpose of the present article is to assess the role of
PCI in SCLC by performing a syste-matic review of the
randomised trials published in the literature. A qualita-
tive evaluation of their methodology was performed, in-
cluding brain imagery work-ups and neuropsychological
assessment as well as an aggregation (meta-analysis) of
survival and brain relapse results.
Materials and Methods
Trials selection
To be eligible for the systematic review, trials needed to
deal with SCLC exclusively, to have randomly assigned
patients to receive prophylactic cranial irradiation or not
and to have been published as a full paper in the French
or English language literature before January 2000.
Articles were identified by an electronic search (Medline)
using the keywords "small cell lung carcinoma" and "pro-
phylactic cranial irradiation" completed by the personal
bibliography of one of the authors and by the references
reported in the selected studies.
Methodological assessment
To assess the trial methodology, nine investigators, in-
cluding six physicians, one biostatistician, one biologist
and one pathologist read each publication, guarantying
the critical reading of the selected articles. They were
then scored according to two quality scales: the score
proposed by Chalmers et al. [12] and the score proposed
by the European Lung Cancer Working Party (ELCWP)
[13, 14] as described in Appendix A. The participation of
many readers was a guarantee for the correct reading of
the articles. The Chalmers score evaluates two dimen-
sions of quality: the internal (scientific) and external
(generalisability of results) validities, with respectively
maximal scores of 63 and 25 points (the total being 88
points). The ELCWP score assesses two quality aspects:
the protocol design (as usually reported in the patients
and methods section of the publication) and the analysis
performance (as reported in the results section) with
maximal scores of 70 and 80 points respectively (with anBMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
overall maximum of 150 points). Each item was quoted
using an ordinal scale (possible values: 2, 1 or 0). When
an item was not applicable in a trial, its theoretically at-
tributable points were not taken into account in the total
of the concerned category. As the items were defined by
data that could objectively be found in the article and did
not require a subjective judgement, the score of each
item was consensually determined in meetings where at
least two thirds of the investigators needed to be present.
The final score was expressed in percentage ranging
from 0 to 100 %, higher values reflecting a larger appli-
cation of methodological standards.
Statistical methods
The results of a study were considered as "positive" if the
p value for the statistical test comparing the survival dis-
tributions between arms was < 0.05 in favour of the ex-
perimental arm. In the other situations (statistically
significant survival benefit for the control arm or non
statistically significant difference in survival distribu-
tions), it was called "negative". The same method was
used to evaluate the time to relapse in the brain. The cor-
relation between the quality scores, or two other contin-
uous variables, was measured by the Spearman ranks
correlation coefficient. Its significance was assessed by
testing a null hypothesis of equality to zero of this coeffi-
cient. Non-parametric Mann-Whitney (for binary varia-
bles) or Kruskal-Wallis (for multiple classes variables)
tests were performed to compare quality scores distribu-
tions according to the value of the considered discrete
variable. For the quantitative aggregation of the survival
results, we measured the treatment effect by the hazard
ratio (HR) between the survival distribution, according
to a method that we have previously reported [15]. For
each trial, this HR was estimated by a method depending
on the results provided in the publications. The most ac-
curate method consisted to retrieve the HR estimate and
its confidence interval from the reported results or to cal-
culate them directly using parameters given by the au-
thors: the confidence interval for the HR, the log-rank
statistics or its p value or the O-E statistic (difference be-
tween numbers of observed and expected events). If not
available, we looked for the total number of events and
the log-rank statistic or its p value allowing calculation of
an approximation of the HR estimate. Finally, if the ex-
ploitable data were in the format of graphical represen-
tations of the survival distributions, we extracted
survivals rates at some specified times in order to recon-
struct the HR estimate and its variance with the assump-
tion that the rate of patients censored was constant
during the study follow-up. By convention a HR < 1 im-
plied a survival benefit for the experimental arm. The
same method was used for time to relapse of the brain
(assessing brain metastases incidence).
Table 1: Trials characteristics
Authors Dates Stage Cerebral PCI (Gray) Timing of PCI N patients
work-up administration
Jackson [18] 1977 1 2 30 1 29
Beiler [24] 1979 1 2 24 1 54
Hansen [22] 1980 2 2 40 3 109
Maurer [26] 1980 1 2 30 1 153
Eagan [20] 1981 2 1 36 3 30
Aisner [27] 1982 1 1 30 2 29
Seydel [21] 1985 2 2 30 1 217
Niiranen [25] 1989 2 2 40 1 51
Ohonoshi [23] 1993 1 1 40 2 46
Arriagada [16] 1995 1 1 24 2 294
Gregor [19] 1997 2 3 8 - 40 2 314
Laplanche [17] 1998 1 1 24 2 211
Stage: 1: all 2: limited disease Cerebral work-up: 1: brain CT scan 2: brain scintigraphy 3: clinical Timing: 1: at initiation of chemotherapy 2: CR con-
solidation 3: consolidation onlyBMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
Results
A total of 12 randomised trials [16–27] published be-
tween 1977 and 1998 were found to be eligible for the
present systematic review. Their main characteristics are
summarised in table 1. The total number of eligible pa-
tients included was 1547; the number of patients by
study ranged from 29 to 314 patients (with a median of
81 patients). Seven hundred and ninety eight patients
were randomly assigned to the PCI group and 749 pa-
tients to the control group. Five studies (894 patients)
[16, 17, 19, 23, 27] evaluated the role of PCI in SCLC pa-
tients who had a complete response after induction
chemotherapy. Five studies [18, 21, 24, 25, 26] assessed
the role of PCI administered at induction chemotherapy
in patients considered as free of brain metastases. In two
studies [20, 22], PCI was given as treatment consolida-
tion at the end of chemotherapy before response evalua-
tion. Seven trials [16, 17, 18, 23, 24, 26, 27] included
SCLC patients at all stages of this disease and five studies
[19, 20, 21, 22, 25] only limited disease. Brain CT scan
was done at the initial staging work-up in five studies [16,
17, 20, 23, 27] and brain scintigraphy in six [18, 21, 22,
24, 25, 26]. In one study [19], the staging was only based
on clinical examination. The dose of cranial irradiation
ranged from 24 to 40 Gy (except in Gregor's study where
it was comprised between 8 and 40 Gy). Quality score as-
sessments of the studies are shown in table 2. The overall
median quality ELCWP score was 38.8 % (ranging from
24.2 to 70.3 %) with respective protocol design and ana-
lyse performance median subscores of 37.7 % (range:
25.0 - 81.0) and 35.2 % (range: 23.1 - 70.9). The linear
correlation between protocol design and analyse per-
formance was statistically significant (Rs = 0.75; p =
0.005). The overall median Chalmers quality score was
32.6 % (range: 11.4 - 75.9 %). There was a significant cor-
relation between both scores (Rs = 0.85; p < 0.001).
There was also a significant difference for ELCWP score
according to the year of publication (Rs = 0.71; p = 0.01),
with better quality score for the new recent studies.
The most poorly described items of the ELCWP scale
were the work-ups including neuropsychological tests
(with a mean score of 22 %), the evaluation criteria (27
%) and the treatment description (33 %) for the internal
validity, the prognostic factors for relapse (0 %) or for
survival (0 %) and the description of the neurological
toxicities (14 %) for the external validity.
Half of the individual studies reported an improvement
of time to relapse in the brain assessing incidence brain
metastases [16, 18, 19, 25, 26, 27] in the PCI arm but
none showed an advantage in term of survival. For the
meta-analysis of brain metastases incidence, data were
available in 10 trials. The hazard ratio (HR) was provided
in 2, it was calculated from the logrank statistic and he
number of events in 7 or from the brain metastases inci-
dence curves in one. The meta-analysis revealed a signif-
icant decrease in the incidence of brain metastases when
all the studies were considered (fig 1) with a hazard ratio
(HR) of 0.48 (95 % CI: 0.39 - 0.60) and when only pa-
Table 2: Quality Scores assessment
Authors ELCWP Score Chalmers Score SMA BMI MA
PD (%) AP (%) Total (%) IV (%) EV (%) Total (%)
Arriagada [16] 81.0 70.9 70.3 84.2 54.5 75.9 Yes Yes
Laplanche [17] 59.3 58.1 58.7 50.0 40.9 47.6 Yes Yes
Jackson [18] 30.3 35.7 33.2 21.0 27.2 22.8 Yes Yes
Gregor [19] 69.0 49.6 58.7 59.5 27.2 51.1 Yes Yes
Eagan [20] 33.0 40.4 36.9 28.5 20.4 24.7 Yes No data
Seydel [21] 25.0 28.0 26.6 14.3 13.6 14.1 Yes Yes
Hansen [22] 52.3 31.6 41.3 47.6 40.9 45.9 Yes No data
Ohonoshi [23] 38.0 43.1 40.7 42.8 54.5 47 Yes Yes
Beiler [24] 25.4 23.1 24.2 33.3 13.6 28.2 Yes Yes
Niiranen [25] 48.9 34.7 41.3 40.4 27.3 37 Yes Yes
Maurer [26] 36.9 31.1 33.8 23.8 13.6 22.3 Yes Yes
Aisner [27] 37.4 28.7 32.8 10.5 13.6 11.4 No data Yes
Mean 44.7 39.6 41.5 38.0 28.9 35.7
Median 37.7 35.2 38.8 36.9 27.2 32.6
PD : protocol designed AP : analysis performance ELCWP : European Lung Cancer Working Party IV : internal validity EV : external validity SMA : 
survival meta-analysis (studies evaluables) BMI : brain metastasis incidence meta-analysis (studies evaluables)BMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
tients in CR were considered (fig 2) with a HR of 0.49 (95
% CI: 0.39 - 0.62). For the meta-analysis of survival, data
were available in 11 trials. The hazard ratio was provided
in 3, it was calculated from the logrank statistic and the
number of events in 6 or from the survival curves in 2.
The meta-analysis showed the absence of improvement
for survival when all the studies were considered (HR:
0.94; 95 % CI: 0.87 -1.02) (fig 3) but revealed an im-
provement in survival when PCI was given to patients in
CR (HR: 0.82; 95 % CI: 0.71 - 0.96) (fig 4).
We also performed some subgroups analysis. The de-
crease in brain metastases incidence was also present in
the subgroups of patients with initial PCI, limited dis-
ease, any stage disease or who had brain CT scan at initial
staging and just before randomisation for PCI (table 3).
Results were not significant for survival in patients with
initial PCI, limited disease or who had no brain CT scan
before randomisation. Statistical significance was mar-
ginal in patients with any stage disease or who had brain
CT scan for initially staging or just before randomisation
for PCI (table 4).
Toxicity was rarely adequately described. There was no
data in four studies. In five trials, authors provided a
short narrative description mentioning no or minimal
toxicity (as alopecia...); Ohonoshi [23] reported one case
of sevenlong-term disease-free survivors who had mem-
Figure 1
Results of the meta-analysis of the studies evaluating the role
of PCI on time to relapse in the brain assessing brain metas-
tases incidence : HR : 0.48 (95% CI : 0.39-0.60) NB: the cen-
tre of the lozenge gives the combined HR of the meta-
analysis and its extremities the 95% confidence interval.
Figure 2
Results of the meta-analysis of the studies evaluating the role
of PCI on time to relapse in the brain assessing brain metas-
tases incidence when patients are in complete response : HR
: 0.49 (95% CI : 0.39-0.62)
Figure 3
Results of the meta-analysis of the studies evaluating the role
of PCI on survival : HR : 0.94 (95 % CI : 0.87-1.02)
Figure 4
Results of the meta-analysis of the studies evaluating the role
of PCI on survival when patients are in CR : HR : 0.82 (95%
CI : 0.71-0.96)BMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
ory disturbance and gait ataxia in the PCI arm. Two trials
reported neuropsychological evaluation in a part of the
randomised patients. Gregor [19] performed an assess-
ment of cognitive function in 40 % of the randomised pa-
tients and showed no difference between the two arms at
two years after PCI but without latter data. Arriagada
[16] evaluated 60 % of the patients two years after PCI
and showed no difference between the two groups.
Discussion
This systematic review, by pooling all randomised stud-
ies comparing treatment of SCLC with or without PCI,
revealed a positive effect of PCI. As shown by the meta-
analysis, PCI reduced brain metastases incidence and
improved survival in patients in CR after chemotherapy
(especially when brain CT scan was part of the staging
work-up). Unfortunately, the performance of brain im-
agery (CT scan or MRI) and the long-term assessment of
neuropsychological toxicities are not well described in
the 12 available trials.
To perform a meta-analysis comparing such heterogene-
ous trials, we have used a methodology that was similar
to our prior systematic reviews [14, 15]. All trials were as-
sessed by 9 investigators using two quality scores: the
Chalmers and the ELCWP scales. The latter scale was
adapted to the present topic by introducing some specific
changes: in the work-up, brain CT scan or MRI with neu-
ropsychological assessment was needed to have 2 points;
in the treatment description, brain irradiation method
had to be described; neuropsychological examination re-
sults were added in the patients characteristics and the
"local control of tumour" item was changed in a "brain
metastases incidence" item. The results obtained with
the two scales were compared and a significant correla-
tion was observed. There was no quality difference
among the publications, allowing quantitative aggrega-
tion (meta-analysis) of the results of the individual trials.
The only significant finding in the performed compari-
sons was an improved quality in favour of more recently
published trials, which can be explained by a better
knowledge of clinical trials methodology standards over
the last years.
Our approach does not however prevent all the potential
biases. The most important one is probably the publica-
tion bias. Our review took into account only fully pub-
lished studies. We did not look for unpublished trials and
abstracts because the methodology used required data
available in full publications only. Meta-analysis based
on individual data is considered by some authors as the
gold standard [28]. Systematic reviews of the literature
and meta-analyses of individual patient data should not
be confused. The first approach is only based on the fully
published studies and provides an exhaustive and critical
analysis of the topic with an adequate methodology
based on the criteria of Mulrow [29] and with data aggre-
gation (meta-analysis) when possible. The second ap-
proach is in fact a new study taking into account all
performed trials on the topic, whatever published or not,
requiring individual data update by the investigators. In
that latter, publications are mainly used for identifica-
tion purposes. Our meta-analysis, based on the pub-
lished data, has allowed us to find the same results for
patients in CR as Auperin et al [4] in their individual data
meta-analysis. This point supports the validity of our ap-
proach. Another potential bias is the language problem:
we have restricted our review to articles published in
English or French. This selection could favour the posi-
tive studies that are most often published in English
while the negative ones tend to be more reported in na-
tive language [30]. The method of extrapolation of HR
needs also to be discussed. When HR were not reported
by the authors, they were calculated from the data avail-
able in the article and, if not possible, they were extrapo-
lated from the survival curves. This approach might have
been associated with errors due to imprecision of the
reading.
The brain work-up is often poorly documented. Only five
studies reported brain CT scan in the initial evaluation
and only in two of them, brain CT scan was done just be-
fore randomisation for PCI (when patients were in CR af-
ter chemotherapy). So, in the majority of the studies, the
CR population could contain patients with asymptomatic
brain metastases for which the delivered PCI was in fact
a consolidation therapy. To be sure that there are no
brain involvement, brain CT scan should have been done
just before PCI. In addition, the CR status depends on
the type of work-up performed and on the presence of le-
sions due to chest irradiation, explaining probably why
some groups report small rates of complete response.
Table 3: Subgroup meta-analysis: role of PCI on time to relapse 
in the brain assessing brain metastases incidence (10 studies 
evaluable)
n studies HR
Initial PCI 5 0.29 (0.12 - 0.71)
Limited disease 3 0.43 (0.28 - 0.64)
All stages diseases 7 0.50 (0.39 - 0.65)
Brain CT scan for staging 4 0.52 (0.40 - 0.68)
Brain CT scan before randomisation 2 0.44 (0.32 - 0.62)
No CT scan before randomisation 2 0.51 (0.38 - 0.63)BMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
Moreover, the recent development of MRI that could re-
veal smaller asymptomatic brain metastases will require
an update of these trials in the next few years. Indeed, in
contrast to prior literature which showed a prevalence of
brain metastases at presentation of 10%, Hochstenbag et
al found a prevalence of 24 %. This difference can been
explained by the fact that the prevalence of 10 % is based
on clinical signs and confirmation by brain imaging and,
that in the Hochstenbag's study, MRI diagnosed 15 %
brain metastases in neurologically asymptomatic pa-
tients [31].
The neuropsychological toxicity of PCI was only de-
scribed in retrospective studies performed with a small
number of patients. In our review, two randomised trials
reported neuropsychological assessments that was per-
formed only in a part of the patients and during the first
years following PCI. They provided no data about long-
term toxicity. It should be noted that other factors than
radiotherapy toxicity can also contribute to neurological
complications. Indeed old age, alcohol, anticancer drugs
(vincristine, etoposide,...), paraneoplastic encephalomy-
elitis [32;33] and tobacco long-term use or can produce
demential syndromes. Concomitant administration of
some types of chemotherapy is considered to contribute
to brain radiotherapy toxicity. The fractionation and the
total dose of radiotherapy delivered to the brain can also
influence the toxicity. Neurological toxicity may be re-
duced by using 2 Gy fractions (20 to 40 Gy) and by giving
PCI after chemotherapy. All these factors were not ana-
lysed in our systematic review because of a total lack of
data in the report of the results of the individual ran-
domised trials.
In conclusion, the present systematic review indicates
that PCI decreases brain metastases incidence and that
PCI improves survival in SCLC patients in CR after
chemotherapy. These effects were obtained in patients
who had no systematic neuropsychological brain image-
ry assessments. The long-term toxicity has so far not
been prospectively evaluated. If PCI can be recommend-
ed in patients with SCLC and CR documented by a work-
up including brain CT scan, data are lacking to generalise
its use to any CR situations as some would like [34]. Par-
ticularly the potential benefits of PCI have to be carefully
balanced with the possible long-term effects, in patients
who are managed with more modern imagery techniques
like MRI. New trials, adapted to these new develop-
ments, are necessary.
Appendix A: ELCWP Quality Score
The attributed value per item is 2 points if it is clearly de-
fined in the article, 1 point if its description is uncom-
plete or unclear and 0 point if it is not defined or
inadequate.
A. Protocol Design
1. definition of the number of participating centres
2. selection criteria:
- PS
- age
- disease stage
- other anticancer treatment
- comorbidity
- histology
3. randomisation method
4. treatment description
- PCI : total dose, fractions, duration, fields, kind of ener-
gy
- dose adaptation plan
5. work-up :
- initial : brain CT scan or MRI and/or neuropsychologi-
cal assessment
- at response assessment (idem)
Table 4: Subgroup meta-analysis: role of PCI on survival (11 stud-
ies evaluable)
n studies HR
Initial PCI 5 1.00 (0.91 - 1.09)
Limited disease 5 0.98 (0.90 - 1.07)
All stages diseases 6 0.84 (0.72 - 0.98)
Brain CT scan for staging 4 0.82 (0.68 - 0.98)
Brain CT scan before randomisation 2 0.78 (0.62 - 0.98)
No CT scan before randomisation 2 0.96 (0.88 - 1.04)BMC Cancer (2001) 1:5 http://www.biomedcentral.com/1471-2407/1/5
- during follow-up after therapy (idem)
- brain CT scan or MRI : systematically or not
6. evaluation criteria
- brain metastases free duration
- survival
- toxicity
- neuropsychological assessment
7. statistical methods
- primary and secondary objectives definition
- statistical methods and tests used
- a priori estimate of sample size
B. Analysis Performance
1. analysis timing
- dates of first and last patient registration
- type of analysis (definitive or planned interim)
2. patients characteristics
- ineligibility rate (per arm)
- causes for ineligibility
- eligible patients characteristics :
- age
- performance status
- sex
- disease extent or stage
- neuropsychological assessment
- time to PCI
- chemotherapy description
- arms balance according to stratification
3. survival
- rates
- crude numbers of deaths
- confidence intervals on rates
- statistical tests results
- intent to treat analysis
4. brain metastases incidence
- rates
- crude numbers of deaths
- confidence intervals on rates
- statistical tests results
- intent to treat analysis
5. neurologic toxicity
- descriptions per arm
- unassessable rate
- statistical tests results
- confidence intervals on rates
6. prognosis factor for survival
- univariate analysis
- multivariate analysis
7. prognosis factor for brain metastases
- univariate analysis
- multivariate analysis
8. discussion
- authors conclusions in accordance with results
- for negative trials : a posteriori estimate of study power
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